דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים: GRI Bio Corporation (GRI)

GRI Bio, Inc. (GRI) focuses on developing NKT therapy to combat fibrosis, aiming to validate drug safety and attract R&D investment. The company utilizes automated cellular platforms in production to eliminate human error. The absence of recurring revenue makes the asset's valuation dependent on the progress of clinical trials. This LTM chart of year-over-year sales volume changes illustrates revenue dynamics, where 0.00 serves as the current metric level.
GRI Bio Inc (GRI) - פילוחי מדדים ודוחות פיננסיים

Defensive assets are selected based on the criterion of sustainable revenue growth; however, GRI Bio, Inc. (GRI) does not yet have stable operating income, remaining dependent on investments and clinical trial outcomes. Under these conditions, the year-over-year sales trend over a 12-month period on GURU.Markets measures the daily relative revenue growth for a rolling year, allowing investors to promptly identify the emergence of commercial drivers.